Immune Checkpoint Inhibitors: all 7,814 studies that test it
Page 25 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.
- An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo)RecruitingNCT04876313Phase 2
- Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based TreatmentRecruitingNCT04875611Phase 2
- Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLCRecruitingNCT04875585Phase 2
- Radiation Free Chemotherapy for Early Hodgkin LymphomaRecruitingNCT04866654Phase 2
- Pembrolizumab and Lenvatinib in Advanced Cervical CancerRecruitingNCT04865887Phase 2
- Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLCRecruitingNCT04865250Phase 2
- Clinical Study of a Personalized Neoantigen Cancer Vaccine Combined With Anti-PD-1 and RFA in Patients With Solid TumorsRecruitingNCT04864379Phase 1
- Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer SubjectsRecruitingNCT04861584Phase 2
- Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT04861467Phase 2
- A Study of Q-1802 in Patients With Advanced Solid TumorsRecruitingNCT04856150Phase 1
- Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)Not yet recruitingNCT04846634Phase 2
- A Multi-center, Non-randomized, Open-label Phase II Clinical Study on the Treatment of Newly Diagnosed Advanced Hodgkin's Lymphoma With PD-1 Antibody (Tislelizumab) Combined With AVD Regimen (Doxorubicin, Vindesine, Dacarbazine) Under the Guidance of PET/CTRecruitingNCT04843267Phase 2
- Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin LymphomaRecruitingNCT04838652Phase 2
- Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin LymphomaRecruitingNCT04837859Phase 2
- Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCCRecruitingNCT04826679Phase 2
- Neoadjuvant Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant NeoplasmsNot yet recruitingNCT04825938Phase 2
- Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular CarcinomaRecruitingNCT04823403Phase 1
- Study of the Safety and Effectiveness of HIFU Combined With REGOTORI for Metastatic Colorectal CancerRecruitingNCT04819516Phase 1
- Improving Public Cancer Care by Implementing Precision Medicine in NorwayRecruitingNCT04817956Phase 2
- PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian CancerRecruitingNCT04815408Phase 2
- Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate CancerRecruitingNCT04812366Phase 2
- Study of PD-1 Antibody and Bevacizumab in the Treatment of High-risk GTN After Combined ChemotherapyRecruitingNCT04812002Phase 2
- Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)RecruitingNCT04807673Phase 3
- Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002)RecruitingNCT04807140Phase 2
- The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular CarcinomaRecruitingNCT04803994Phase 3
- A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBCRecruitingNCT04803539Phase 2/3
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerRecruitingNCT04802759Phase 1/2
- A Phase II Study of TACE Plus PD-1 Antibody in the Locally Advanced Stomach AdenocarcinomaRecruitingNCT04799548Phase 2
- VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid TumorsRecruitingNCT04796012Phase 1/2
- A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid TumorsRecruitingNCT04794972Phase 1
- Phase Ⅱ Trial of Camrelizumab in Patients Without Distant Metastasis Nasopharyngeal CarcinomaRecruitingNCT04782765Phase 2
- Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric CancerRecruitingNCT04781686Phase 2
- Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal CarcinomaRecruitingNCT04778956Phase 3
- The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC.RecruitingNCT04777084Phase 2
- Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)Not yet recruitingNCT04772287Phase 3
- SBRT for Oligo-residual NSCLC After Treatment With PD-1/PD-L1 Immune Checkpoint InhibitorsRecruitingNCT04767009Phase 2
- This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid TumorsRecruitingNCT04762641Phase 1
- PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapyRecruitingNCT04745949Phase 2
- Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in MelanomaRecruitingNCT04741997Early Phase 1
- Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare SubtypeRecruitingNCT04741438Phase 3
- FS222 First in Human Study in Patients With Advanced MalignanciesRecruitingNCT04740424Phase 1
- Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast CancerRecruitingNCT04739670Phase 2
- Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung CancerRecruitingNCT04728724Phase 2
- Exploratory Study of PD-1 Neoadjuvant Treatment of Recurrent MeningiomaRecruitingNCT04728568Not applicable
- A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck CancerRecruitingNCT04722523Phase 1
- Toripalimab Combined With Chemotherapy in Primary Tracheal Squamous Cell CarcinomaNot yet recruitingNCT04716751Phase 2
- Neoadjuvant Toripalimab Combined With Chemotherapy in the Treatment of Malignant Pleural MesotheliomaNot yet recruitingNCT04713761Phase 2
- PD-1 Antibody for The Prevention of Adenomatous Polyps and Second Primary Tumors in Lynch Syndrome PatientsRecruitingNCT04711434Phase 3
- Intralesional Influenza Vaccine for the Treatment of Stage I-IV MelanomaRecruitingNCT04697576Phase 1
- Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based TherapyRecruitingNCT04691817Phase 1/2
- The Study is Being Conducted to Evaluate the Efficacy and Safety of SHR-1316 in Combination With Chemo-radiotherapy in Patients With LS-SCLC.Enrolling by invitationNCT04691063Phase 3
- A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast CancerRecruitingNCT04683679Phase 2
- TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial CarcinomaRecruitingNCT04678362Phase 2
- Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr (CREATIVE Phase IA Trial)RecruitingNCT04678102Phase 1
- Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell CarcinomaRecruitingNCT04671667Phase 2
- Neoadjuvant Short-course Radiotherapy Followed by the Combination of Immunotherapy and Chemotherapy in Locally Advanced Rectal CancerNot yet recruitingNCT04663763Phase 2
- Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCCRecruitingNCT04663035Phase 2
- Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCLNot yet recruitingNCT04659434Phase 2
- Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal CancerRecruitingNCT04659382Phase 2
- Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRCRecruitingNCT04653480Phase 2
- Merck IIT: RRP Pembro and LenvatinibRecruitingNCT04645602Phase 2
- WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOCRecruitingNCT04644289Phase 2
- Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal CancerRecruitingNCT04636008Phase 1/2
- Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract CancerRecruitingNCT04628767Phase 2/3
- PD-1 Inhibitor or PD-1 Inhibitor Plus GVD for Relapsed/Refractory CHLRecruitingNCT04624984Phase 2
- Toripalimab Plus TPF Chemotherapy and Radiotherapy for LA-HPSCCNot yet recruitingNCT04624308Phase 2
- OH2 Injection in Combination With HX008 for Melanoma.RecruitingNCT04616443Phase 1/2
- Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCCRecruitingNCT04615143Phase 2
- Umbrella Biomarker-Guided Therapy in NPCNot yet recruitingNCT04605562Phase 2
- Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHTRecruitingNCT04602377Phase 2
- Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) CancerRecruitingNCT04592211Phase 1/2
- Adriamycin and Ifosfamide Combined With SintilimabRecruitingNCT04589754Phase 2
- Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLCRecruitingNCT04585490Phase 3
- Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue SarcomaRecruitingNCT04577014Phase 1/2
- ONO-4538 Phase II Rollover Study (ONO-4538-98)RecruitingNCT04566380Phase 2
- Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin LymphomaRecruitingNCT04561206Phase 2
- Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPCRecruitingNCT04557020Phase 3
- A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLCRecruitingNCT04550104Phase 1
- A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)RecruitingNCT04547166Phase 2/3
- Imatinib Mesylate in Combination With Pembrolizumab in Patients With MelanomaRecruitingNCT04546074Phase 1/2
- Pilot Study of PD-1inhibitor (Tislelizumab) Plus Chemotherapy as Neoadjuvant Therapy for Limited-Stage Small-Cell Lung CancerRecruitingNCT04542369Phase 2
- PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung CancerRecruitingNCT04539977Phase 2
- GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced SarcomaRecruitingNCT04535713Phase 2
- Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLCRecruitingNCT04530227Phase 2
- Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian CancerRecruitingNCT04519151Phase 2
- The Combination Therapy of TACE and Ablation With Durvalumab in Hepatocellular Carcinoma at Intermediate Stage (TAD)Not yet recruitingNCT04517227Not applicable
- Combination of IV Ascorbic Acid and Adebrelimab in Metastatic Colorectal CancerRecruitingNCT04516681Phase 3
- The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma.RecruitingNCT04514081Phase 2
- Sintilimab Combined With Chidamide in Treating Peripheral T Cell LymphomaRecruitingNCT04512534Phase 2
- A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain MetastasesRecruitingNCT04511013Phase 2
- Study of Pembrolizumab With Bendamustine in Hodgkin LymphomaRecruitingNCT04510636Phase 2
- Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung CancerNot yet recruitingNCT04506242Phase 2
- A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBCRecruitingNCT04501523Phase 2
- Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung CancerRecruitingNCT04499053Phase 2
- A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial CarcinomaRecruitingNCT04486781Phase 2
- A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial CancerRecruitingNCT04486352Phase 1/2
- A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative BreastRecruitingNCT04481763Phase 1/2
- Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular CarcinomaRecruitingNCT04472767Phase 2
- Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLCRecruitingNCT04467723Phase 1/2
- Efficacy and Safety of CRT, Durvalumab and Surgery for SSTNot yet recruitingNCT04465968Phase 3